Argenx, a leading global immunology company, is set to participate in a fireside chat at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 10:00 AM PT in Las Vegas, NV. The event will feature members of the management team and a live webcast of the fireside chat will be available on the Investors section of the Argenx website at argenx.com/investors. A replay of the webcast will also be accessible on the website for approximately 90 days after the event.
Argenx is dedicated to translating immunology breakthroughs into innovative antibody-based medicines through its Immunology Innovation Program (IIP). The company has developed and is currently commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions around the world. In addition to this, Argenx is evaluating efgartigimod in various serious autoimmune diseases and advancing several early-stage experimental medicines within its therapeutic franchises.
Argenx’s mission is to improve the lives of individuals with severe autoimmune diseases by developing innovative therapies that target key immunological pathways. The company’s expertise in immunology and drug development has enabled it to create a pipeline of promising candidates that have shown promise in clinical trials. For more information about Argenx, visit their website at www.argenx.com and follow them on social media platforms like LinkedIn, Twitter, Instagram, Facebook, and YouTube.
For media inquiries, please contact Ben Petok at bpetok@argenx.com. For investor-related questions, reach out to Alexandra Roy (US) at aroy@argenx.com or Lynn Elton (EU) at lelton@argenx.com.